United States· US:51662-1439_f1deeef3-92c7-a88e-e053-2a95a90a74a3
PHYSOSTIGMINE SALICYLATE
A medicinal product containing physostigmine salicylate, registered in United States by HF Acquisition Co LLC, DBA HealthFirst.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- PHYSOSTIGMINE SALICYLATE
- Manufacturer
- HF Acquisition Co LLC, DBA HealthFirst
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 4
- ndc1151662143912 mL in 1 AMPULE (51662-1439-1)
- ndc11516621439310 POUCH in 1 CASE (51662-1439-3) / 1 AMPULE in 1 POUCH (51662-1439-2) / 2 mL in 1 AMPULE
- ndc1151662-1439-1
- ndc1151662-1439-3
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Physostigmine salicylate in 3 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- GermanyAnticholiumDr. Franz Köhler Chemie Gmbh
- CzechiaANTICHOLIUM
- NorwayAnticholiumDr. F. Koehler Chemie
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Austria · Anticholium
- Germany · Anticholium
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f53694e9-d2ef-479c-80a9-13a53027f3fd GET /v1/drugs/f53694e9-d2ef-479c-80a9-13a53027f3fd?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS",
"source": "ndc",
"strength": "1",
"substance": "PHYSOSTIGMINE SALICYLATE",
"productndc": "51662-1439",
"dosage_form": "INJECTION",
"dea_schedule": null,
"strength_unit": "mg/mL",
"application_number": null,
"marketing_category": "UNAPPROVED DRUG OTHER"
}See everything about physostigmine salicylate.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.